Anavex life sciences to present at the h.c. wainwright 2nd bioconnect investor conference at nasdaq

New york, may 14, 2024 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including alzheimer's disease, parkinson's disease, rett syndrome, schizophrenia, and other central nervous system (cns) diseases, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in a fireside chat at the h.c. wainwright 2nd bioconnect investor conference at nasdaq being held may 20th, 2024 at 10:00am et at nasdaq world headquarters new york city.
AVXL Ratings Summary
AVXL Quant Ranking